The winning weapon is within reach of the lupus erythematosus marathon line soon

Physician News (Fengfeng, RongMedia reporter) "I found that many people are not born to appreciate the beauty of peacocks.

" Said Flannery O'Connor, the most outstanding writer in the southern United States after Faulkner .
.

Being diagnosed with systemic lupus erythematosus (SLE) at the age of 25 allowed O'Connor to appreciate the beauty of life from another angle.

It is a pity that there was no effective treatment for SLE more than 60 years ago, and the side effects of drugs were also serious.
The disease progression and organ damage seriously affected her life and health.

What is gratifying is that the current SLE treatment pattern has already undergone earth-shaking changes.

At the first annual meeting of the National Clinical Research Center for Skin and Immune Diseases held recently, Professor Li Mengtao from the Department of Rheumatology and Immunology of Peking Union Medical College Hospital and Professor Munther Khamashta, Director of the Lupus Research Laboratory of St.
Thomas Hospital in London, shared their experience in real-world treatment of SLE.
Professor Li Mengtao Also accepted an exclusive interview with a reporter from "Physician Daily".

SLE treatment Long-distance running targeted therapy is the key to success.
Professor Li Mengtao Professor Li Mengtao introduced that SLE is a very complex disease.
A clear treatment goal can help doctors to adjust the treatment plan in the later follow-up.

The principle of "standard treatment" is very clear, and disease remission and low disease activity are ideal goals pursued by doctors.

However, to achieve complete remission of the disease, current treatment methods are still lacking.

International guidelines also point out that achieving disease remission is the ideal goal of SLE treatment.
If disease remission cannot be achieved, achieving low disease activity is the achievable treatment goal of SLE treatment.

In order to achieve standard treatment, SLE treatment strategies have been continuously improved.

With the exploration of diseases and the development of innovative drugs, this treatment goal is now within reach.

Real-world treatment research data show that the use of belyumumab can help patients significantly reduce the amount of hormones, reduce the risk of recurrence, and delay the progression of organ damage.

Professor Li said that the response rate of belyumumab in highly active SLE patients is as high as 70.
4%; long-term use of belyumumab can delay the progression of organ damage in more than 85% of patients.

Such real-world data is very gratifying for both SLE patients and rheumatologists.

For a long time, it can be said that the treatment of SLE has been in a state of lack of medicine and medicine.
In the face of difficult patients, doctors will inevitably feel powerless.

Now that belyumumab has such excellent real-world treatment data, rheumatologists feel that they finally have a powerful weapon in their hands.

For patients, another good news is that the expensive belimumab has entered medical insurance.

The treatment of SLE is like a marathon.
It is not only a short-term control of disease activity, but also a long-term stabilization of the disease and reduction of long-term organ damage in order to achieve the effect of "standard treatment", so the medication will take longer, which will undoubtedly be Bring a certain economic burden to the patient's family.

After entering the medical insurance, the price of drugs has been drastically reduced, which has greatly improved the availability of drugs, and the benefits brought by them are multi-dimensional.

Make it affordable for SLE patients who need long-term use of belyumumab, thereby improving the therapeutic effect of SLE and improving the overall prognosis of patients.

Real-world treatment data fully affirm the SLE immune combination therapy Professor Munther, Professor Munther introduced that, as we all know, there are many cytokines and lymphocytes involved in the disease process of SLE, and B lymphocyte stimulating factor (BLyS) is one of them.

There are many evidences that BLyS is related to the pathogenesis of SLE.

Compared with healthy people, SLE patients have higher BLyS levels.

There is a strong correlation between high levels of BLyS and high levels of anti-ds-DNA.

Moreover, high levels of BLyS are significantly related to the worsening of SLE.

It can be seen that BLyS plays an important role in the pathogenesis of SLE.

Therefore, it is also known as a potential target for SLE treatment.

The Phase III clinical trial of belyumab started in 2007 and was completed in 2011.
Subsequently, its observational trials in the real world have been carried out in various parts of the world.

There are many research results worthy of attention.

The OBSErve study showed that the SELENA-SLEDAI scores of the included SLE patients treated with belimumab for 6 months were significantly lower than the baseline level.
It is worth mentioning that the follow-up time in Argentina and the United States was extended to 24 During the month, it was observed that the SELENA-SLEDAI score of the patient remained stable.

The patient's hormone consumption was reduced by 6-12 mg/d from the baseline level.

Professor Munther emphasized that long-term use of hormones can lead to organ damage, and belyumumab can help SLE patients to reduce the dose of hormone use, which is of great clinical significance.

In addition, a Toronto organ damage propensity score matching study explored the effect of long-term use of belimumab on reducing patients' organ damage through clever experimental design.

The results showed that the SDI score of SLE patients after 5 years of combined treatment with belyumumab was significantly reduced.

In addition, compared with patients who received only conventional treatment, patients who received belyumumab combination therapy had a 61% lower risk of disease progression to a higher SDI score during the follow-up period, and the proportion of patients whose SDI score increased by ≥2 points was also significant.
reduce.

It can be seen that, as the first biologic agent officially approved by the FDA for SLE in the past 60 years, belyumumab can not only effectively reduce the disease activity of SLE, reduce the amount of hormones in the treatment process, reduce the risk of recurrence, and prevent long-term The effect on organ damage is also very obvious.

Typesetting: Li Hui Editor: Fengfeng Review: Fengfeng For more information, please click: Interdisciplinary Dialogue | Oncologists, neuroscientists, and reproductive specialists talk about breast cancer "chronic disease" management for a century and a medical monument | Zou Duo Wu: When MDT empowers the outpatient clinic to show the true strength of the discipline, the "Physician Daily" award-winning survey is waiting for you to participate in the "Physician Daily" submission Public email: yishibao2017@163.
com [Note] Some pictures are from the Internet and WeChat Moments.
Respected pictures Hello, author, the doctor's newspaper has prepared the manuscript fee for you, please contact the editor on duty: 010-58302828-6808.
Currently 1,1330,000+ doctors have been following to join us